Skip to main content
. 2012 Sep 12;2012(9):CD009157. doi: 10.1002/14651858.CD009157.pub2

Price 2011.

Methods A cost‐utility analysis based on a Markov model, from a German healthcare provider perspective
Participants Patients with moderate to severe COPD
Interventions indacaterol versus tiotropium or salmeterol
Outcomes FEV1, mortality, exacerbations, cost, ICER
Notes